Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma.
Houot R, Poeschel V, Altmann B, Angel S, Thurner L, Illmer T, Andre M, Dreyling M, Maisonneuve H, Tilly H, Mayer S, Casasnovas O, Le Gouill S, Offner F, Cartron G, Kerkhoff A, Weber T, Hoffmann J, Ziepert M, Klapper W, Itti E, Hellwig D, Natchkebia G, de Leval L, Rosenwald A, Haioun C, Dercle L, Gaulard P, Held G. Houot R, et al. Hemasphere. 2022 Jan 10;6(2):e672. doi: 10.1097/HS9.0000000000000672. eCollection 2022 Feb. Hemasphere. 2022. PMID: 35028526 Free PMC article.
Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.
Houot R, Le Gouill S, Ojeda Uribe M, Mounier C, Courby S, Dartigeas C, Bouabdallah K, Alexis Vigier M, Moles MP, Tournilhac O, Arakelyan N, Rodon P, El Yamani A, Sutton L, Fornecker L, Assouline D, Harousseau JL, Maisonneuve H, Caulet-Maugendre S, Gressin R; French GOELAMS group. Houot R, et al. Ann Oncol. 2012 Jun;23(6):1555-61. doi: 10.1093/annonc/mdr450. Epub 2011 Oct 19. Ann Oncol. 2012. PMID: 22012966 Free article. Clinical Trial.
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Béné MC, Martin A, Lamy T. Damaj G, et al. Among authors: houot r. J Clin Oncol. 2013 Jan 1;31(1):104-10. doi: 10.1200/JCO.2012.43.7285. Epub 2012 Oct 29. J Clin Oncol. 2013. PMID: 23109692 Clinical Trial.
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.
Bachy E, Houot R, Morschhauser F, Sonet A, Brice P, Belhadj K, Cartron G, Audhuy B, Fermé C, Feugier P, Sebban C, Delwail V, Maisonneuve H, Le Gouill S, Lefort S, Brousse N, Foussard C, Salles G; Groupe d'Etude des Lymphomes de l'Adulte (GELA). Bachy E, et al. Among authors: houot r. Haematologica. 2013 Jul;98(7):1107-14. doi: 10.3324/haematol.2012.082412. Epub 2013 May 3. Haematologica. 2013. PMID: 23645690 Free PMC article. Clinical Trial.
A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Ribrag V, Dupuis J, Tilly H, Morschhauser F, Laine F, Houot R, Haioun C, Copie C, Varga A, Lambert J, Hatteville L, Ziti-Ljajic S, Caron A, Payrard S, Coiffier B. Ribrag V, et al. Among authors: houot r. Clin Cancer Res. 2014 Jan 1;20(1):213-20. doi: 10.1158/1078-0432.CCR-13-0580. Epub 2013 Oct 16. Clin Cancer Res. 2014. PMID: 24132920 Clinical Trial.
Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA.
Houot R, Soussain C, Tilly H, Haioun C, Thieblemont C, Casasnovas O, Bouabdallah K, Morschhauser F, Le Gouill S, Salles GA, Hoang-Xuan K, Choquet S, Marchand T, Laurent C, Pangault C, Lamy T. Houot R, et al. Ann Oncol. 2016 Jul;27(7):1349-50. doi: 10.1093/annonc/mdw138. Epub 2016 Mar 21. Ann Oncol. 2016. PMID: 27002105 Free article. Clinical Trial. No abstract available.
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, Morschhauser F, Navarro R, Le Gouill S, Haioun C, Houot R, Casasnovas O, Holte H, Lamy T, Broussais F, Payrard S, Hatteville L, Tilly H. Coiffier B, et al. Among authors: houot r. Br J Haematol. 2016 Jun;173(5):722-30. doi: 10.1111/bjh.13992. Epub 2016 Mar 24. Br J Haematol. 2016. PMID: 27010483 Free article. Clinical Trial.
Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.
Reboursiere E, Le Bras F, Herbaux C, Gyan E, Clavert A, Morschhauser F, Malak S, Sibon D, Broussais F, Braun T, Fornecker LM, Garidi R, Tricot S, Houot R, Joly B, Abarah W, Choufi B, Pham AD, Gac AC, Fruchart C, Marin E, Safar V, Parcelier A, Maisonneuve H, Bachy E, Cartron G, Jaccard A, Tournilhac O, Rossi C, Schirmer L, Martignoles JA, Gaulard P, Tilly H, Damaj G; From the Lymphoma Study Association (LYSA) centers. Reboursiere E, et al. Among authors: houot r. Oncotarget. 2016 Dec 20;7(51):85573-85583. doi: 10.18632/oncotarget.10764. Oncotarget. 2016. PMID: 27458168 Free PMC article.
212 results